Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia

Eisendle, Klaus; Lang, Alois; Eibl, Brigitte; Nachbaur, David; Glassl, H.; Fiegl, Michael; Thaler, J.; Gastl, Guenther

doi:10.1046/j.1365-2141.2003.03979.x

Cited by 35 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DCs display impaired maturation in response to LPS and PGE 2 treatment and impaired migration as compared to monocyte-derived DCs. 8 Fortunately, our data showed no significant functional defects in AML-derived APCs with respect to maturation and migration as compared to normal CD34 þ cell-derived DCs.…”

Section: To the Editormentioning

confidence: 86%

Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity

et al. 2005

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 86%

Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity

et al. 2005

View full text Add to dashboard Cite

“…Using the KEGG pathways to analyze targets of dysregulated miRNAs across the progression of CML, we have found that many dysregulated potential target molecules were involved in several biological pathways including metabolic and cancer pathways, the MAPK signaling pathway, endocytosis, cytokine-cytokine receptor interaction and focal adhesion. Recent studies have confirmed that pathogenesis and progression of CML were closely related to the MAPK signaling pathway [27,28], endocytosis [29,30] and focal adhesion [31,32].…”

Section: Oncotarget S474 Wwwimpactjournalscom/oncotargetmentioning

confidence: 97%

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

Zhang¹,

Jiang²,

Han³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

ABSTRACTmicroRNAs play important regulatory roles in hematologic malignancies, and dysregulation of circulating miRNAs serves as diagnostic, prognostic and predictive biomarkers in many diseases. The correlation of plasma miRNA profiles with the progression of chronic myeloid leukemia (CML) has not been investigated. We have applied microarrays to identify differentially expressed miRNAs, followed by qRT-PCR to validate candidate miRNAs from four sample pools including chronic phase (CP), accelerated phase(AP), blast crisis(BC) and healthy control. Clustering analyses revealed varying phase-specific patterns of plasma miRNA expression during CML progression. Different phases of CML showed differential expression profiles between sample pools during the progression. The functional annotation tool, DAVID, found that putative targets of dysregulated miRNAs in different phases of diease are involved in several important signaling pathways. Gradually decreased expression levels of miR-451a were validated in CML patients from the CP to AP and BC; when CML patients achieved major molecular response (MMR), miR-451a expression was increased and restored to normal range. These data provide an important resource for studies on CML progression and allow a better understanding of the fundamental differences in plasma miRNA expression profiles among the different phases of CML.

show abstract

“…For use in immunotherapy, dendritic cells are generated and pulsed with tumor-specific antigens under in vitro conditions [2,3]. Usually, peripheral blood monocytes are used as DC precursors [4]. In patients with myeloid leukemias, dendritic cells (DC) may originate from leukemic cells and thus may also express leukemia-specific antigens.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Hus

Tabarkiewicz²,

Lewandowska³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Immunotherapy with dendritic cells (DC) may constitute a new and advantageous option for patients with chronic myeloid leukemia (CML) who respond to therapy with tyrosine kinase inhibitors (TKI), but do not reach complete cytogenetic or molecular remission. In this study, we evaluated the immunophenotype of DC generated from monocytes (Mo-DC) of patients with CML and the influence of TKI therapy on the results of CML-DC generation. We also measured the percentages of T regulatory cells (Tregs) as well as Th17 cells in 19 untreated patients suffering from CML, and in 28 CML patients treated with TKI. We found that DC can be reliably generated from the peripheral blood CD14 + cells of untreated CML patients. But we observed a persistent expression of CD14 monocyte marker on DC from CML patients, together with lower percentages of Mo-DC with expression of CD1a (p = 0.002), CD80 (p = 0.0005), CD83 (p = 0.0004), and CD209 (p = 0.02) compared to healthy donors. There was an adverse correlation between WBC count and the percentage of Mo-DC with co-expression of CD80 and CD86 (R = -0.63; p = 0.03). In patients treated with TKI, we observed higher efficacy of DC generation in seven-day cultures, compared to untreated patients. Expression of CD209 on DC was higher in patients treated with TKI (0.02). The duration of TKI therapy correlated adversely with MFI for CD1a (R = -0.49; p = 0.006) and positively with MFI for CD83 (R = 0.63; p = 0.01). Percentages of CD4 + CD25 high FoxP3 + cells (p = 0.0002) and Th17 cells (p = 0.02) were significantly higher in untreated CML patients compared to healthy controls. There was a significant correlation between the percentage of Treg cells and the percentage of peripheral blood basophiles (R = 0.821; p = 0.02). There were no changes in Tregs or Th17 cell percentages in CML patients after six months of TKI therapy. However, the expression of intracellular IL-17 in Th17 cells correlated negatively with the time of TKI therapy in the whole group of treated patients (R = -0.516; p = 0.04). We noted a correlation between IL-6 serum level and peripheral blood WBC count (R = 0.492; p = 0.04). There was also an inverse correlation between the serum level of IL-6 and the duration of TKI therapy (R = -0.66; p = 0.03). Taken together, our data shows that mature DC can be generated from CML patients treated with TKI, and that the yield of Mo-DC is higher in patients treated with TKI than in patients with active disease. This should encourage further trials with DC immunotherapy in patients with cytogenetic response after TKI therapy. We also found increased frequencies of T regulatory and Th17 cells in CML patients, which might suggest their potential role in immunity against 154

show abstract

Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia

Cited by 35 publications

References 42 publications

Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity

Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity

WITHDRAWN: Expression profiles and biological implications of plasma miRNAs associated with chronic myeloid leukemia phases

Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Contact Info

Product

Resources

About